Variant | Number of patients with the gene alternation (percentage) | P | ||
---|---|---|---|---|
Whole cohort | Low BDH2, expression | High BDH2, expression | ||
NPM1 mut | 36 (31.85%) | 16 (28.07%) | 20 (35.71%) | 0.271 |
FLT3- ITD | 23 (20.35%) | 7 (12.28%) | 16 (28.57%) | 0.030* |
FLT3- TKD | 8 (7.08%) | 5 (8.77%) | 3 (5.36%) | 0.338 |
NPM1mut/FLT3- ITDneg | 20 (17.70%) | 11(19.30%) | 9 (16.07%) | 0.368 |
CEBPA a | 34 (30.09%) | 16 (28.07%) | 18 (32.14%) | 0.444 |
CEBPA Double mutation | 9 (7.96%) | 3 (5.26%) | 6 (10.71%) | 0.593 |
IDH1 b | 3 (3.75 %) | 1 (2.56 %) | 2 (4.88%) | 0.592 |
IDH2 b | 8 (10 %) | 3 (7.69%) | 5 (12.20%) | 0.508 |
DNMT3A b | 12 (15 %) | 10 (25.641%) | 2 (4.88%) | 0.009* |
MLL b | 7 (8.75%) | 3 (7.69%) | 4 (9.76%) | 0.426 |
ERG c | 11.17 (10.26-12.08) | 11.60 (10.48-12.72) | 10.68 (9.17-12.20) | 0.320 |
MN1 c | 12.98 (12.28-13.68) | 13.35 (12.42-14.28) | 12.55 (11.47-13.64) | 0.257 |
miR-181a c | 3.12 (2.57-3.67) | 3.17 (2.35-3.98) | 3.07 (2.30-3.84) | 0.864 |
miR-3151 c | 12.35 (11.90-12.80) | 12.18 (11.53-12.84) | 12.53 (11.89-13.16) | 0.448 |